Anti-Leu2, Recombinant [UCH-T4]
Invented by Prof Peter Beverley from Imperial College
- References (2)
- Inventor Info
|Applications||FACS IHC IF|
|Antigen/Gene or Protein Targets||Leu2 (CD8)|
|Relevance||Leu-2 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. Leu-2 is present on human suppressor / cytotoxic T cells, 30% of circulating T cells. UCH-T4 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of T4/T8 ratios in immune deficiencies, rheumatoid arthritis, multiple sclerosis, etc.|
|Immunogen||Thymocytes followed by Sezary T cells.|
|Research Area||Immunology, Stem Cell Biology|
Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
Three different versions available:
- Anti-CD8 [UCHT4], Mouse IgG2a, Kappa
- Anti-CD8 [UCHT4], Mouse IgG2a, Kappa, containing key point mutations that abrogate binding to Fc gamma receptors.
- Anti-CD8 [UCHT4], Rabbit IgG, Kappa
There are 2 reference entries for this reagent.View All References
Add an inventor